Recommendations for myasthenia gravis clinical trials

Muscle and Nerve

Volumn 45, Issue 6, 2012, Pages 909-917

  Benatar, Michael ^a   Sanders, Donald B ^b   Burns, Ted M ^a,c   Cutter, Gary R ^a,d   Guptill, Jeffrey T ^a,b   Baggi, Fulvio ^e   Kaminski, Henry J ^a,f   Mantegazza, Renato ^e   Meriggioli, Matthew N ^g   Quan, Joanne ^h   Wolfe, Gil I ^a,i   Barohn, Richard J ^a   Howard, James F ^a   Antegazza, R ^a   Merrigioli, Matthew N ^a   Piantadosi, Steven ^a   Smirnow, Alexis ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e DEPARTMENT OF NEUROSURGERY   (Italy)

^f GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^g UNIVERSITY OF ILLINOIS   (United States)

^h SUNY School of Medicine and Biomedical Sciences ^*  (United States)

ⁱ UNIVERSITY AT BUFFALO   (United States)

Author keywords

All clinical trials; Clinical trials methodology study design; Myasthenia; Outcome measures; Quality of life

Indexed keywords

BIOLOGICAL MARKER; CHOLINESTERASE INHIBITOR; IMMUNOMODULATING AGENT; STEROID;

ARTICLE; CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); HEALTH CARE ORGANIZATION; HUMAN; MEDICAL SOCIETY; MYASTHENIA GRAVIS; PRIORITY JOURNAL; REGISTER;

EID: 84860897376     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.23330     Document Type: Article

References (50)

1. Jaretzki A, Barohn RB, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS, et al. Myasthenia gravis. Recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 2000; 55: 16-23.
2. Palace J, Newsom-Davis J, Lecky B, The Myasthenia Gravis Study Group. A randomized double-blind trial of prednisolone alone or with a zathioprine in myasthenia gravis. Neurology 1998; 50: 1778-1783.
3. Myasthenia Gravis Clinical Study Group. A randomised clinical trial comparing prednisone and azathioprine in myasthenia gravis. Results of the second interim analysis. J Neurol Neurosurg Psychiatry 1993; 56: 1157-1163.
4. Sanders DB, Hart IK, Mantegazza R, Shukla SS, Siddiqi ZA, De Baets MHV, et al. An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis. Neurology 2008; 71: 400-406.
5. Muscle Study Group. A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis. Neurology 2008; 71: 394-399.
6. Tindall RSA, Rollins JA, Phillips JT, Greenlee RG, Wells L, Belendiuk G. Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis. N Engl J Med 1987; 316: 719-724.
7. Tindall RSA, Phillips JT, Rollins JA, Wells L, Hall K. A clinical therapeutic trial of cyclosporine in myasthenia gravis. Ann N Y Acad Sci 1993; 681: 539-551.
8. Barohn RJ. Efficacy of methotrexate in myasthenia gravis. In. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). [Accessed 2008 Dec 23].
9. Alexion Pharmaceuticals. Safety and efficacy study of eculizumab in patients with refractory generalized myasthenia gravis. In. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). [Accessed 2008 July 30].
10. Aban IB, Wolfe GI, Cutter GR, Kaminski HJ, Jaretzki A, Minisman G, et al. The MGTX experience: challenges in planning and executing an international, multicenter clinical trial. J Neuroimmunol 2008; 201: 80-84.
11. Benatar M. Efficacy of prednisone in the treatment of ocular myasthenia (EPITOME). In. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). [Accessed 2009 Oct 14].
12. Wolfe GI, Barohn RJ, Foster BM, Jackson CE, Kissel JT, Day JW, et al. Randomized, controlled trial of intravenous immunoglobulin in myasthenia gravis. Muscle Nerve 2002; 26: 549-552.
13. Gajdos P, Tranchant C, Clair B, Bolgert F, Eymard B, Stojkovic T, et al. Treatment of myasthenia gravis exacerbation with intravenous immunoglobulin. A randomized double-blind clinical trial. Arch Neurol 2005; 62: 1689-1693.
14. Zinman L, Ng E, Bril V. IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial. Neurology 2007; 68: 837-841.
15. Ronager J, Ravnborg M, Hermansen I, Vorstrup S. Immunoglobulin treatment versus plasma exchange in patients with chronic moderate to severe myasthenia gravis. Artif Organs 2001; 25: 967-973.
16. Gajdos P, Chevret S, Clair B, Tranchant C, Chastang C. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group. Ann Neurol 1997; 41: 789-796.
17. Barth D, Nabavi Nouri M, Ng E, Nwe P, Bril V. Comparison of IVIg and PLEX in patients with myasthenia gravis. Neurology 2011; 76: 2017-2023.
18. Sanders DB, Siddiqi ZA. Lessons from two trials of mycophenolate mofetil in myasthenia gravis. Ann N Y Acad Sci 2008; 1132: 249-253.
19. Bedlack RS, Simel DL, Bosworth H, Samsa G, Tucker-Lipscomb B, Sanders DB. Quantitative myasthenia gravis score: assessment of responsiveness and longitudinal validity. Neurology 2005; 64: 1968-1970.
20. Barohn RJ, McIntire D, Herbelin L, Wolfe GI, Nations S, Bryan WW. Reliability testing of the quantitative myasthenia gravis score. Ann N Y Acad Sci 1998; 841: 769-772.
21. Sanders DB, Tucker-Lipscomb B, Massey JM. A simple manual muscle test for myasthenia gravis: validation and comparison with the QMG score. Ann N Y Acad Sci 2003; 998: 440-444.
22. Paul RH, Nash JM, Cohen RA, Gilchrist JM, Goldstein JM. Quality of life and well-being of patients with myasthenia gravis. Muscle Nerve 2001; 24: 512-516.
23. Padua L, Evoli A, Aprile I, Caliandro P, Mazza S, Padua R, et al. Health-related quality of life in patients with myasthenia gravis and the relationship between patient-oriented assessment and conventional measurements. Neurol Sci 2001; 22: 363-369.
24. Mullins LL, Carpentier MY, Paul RH, Sanders DB; Muscle Study Group. A disease-specific measure of quality of life for myasthenia gravis. Muscle Nerve 2008; 38: 947-956.
25. Burns TM, Conaway MR, Cutter GR, Sanders DB; Muscle Study Group. Less is more, or almost as much: a 15-item quality-of-life instrument for myasthenia gravis. Muscle Nerve 2008; 38: 957-963.
26. Burns TM, Conaway M, Cutter GR, Sanders DB; Muscle Study Group. Construction of an efficient evaluative instrument for myasthenia gravis: the MG composite. Muscle Nerve 2008; 38: 1553-1562.
27. Burns TM, Conaway M, Sanders DB; MG Composite and MG-QOL, 15 Study Group. The MG composite: a valid and reliable outcome measure for myasthenia gravis patient care. Neurology 2010; 74: 1434-1440.
28. Mantegazza R, Antozzi C, Peluchetti D, Sghirlanzoni A, Cornelio F. Azathioprine as a single drug or in combination with steroids in the treatment of myasthenia gravis. J Neurol 1988; 235: 449-453.
29. Burns TM. History of outcome measures for myasthenia gravis. Muscle Nerve 2010; 42: 5-13.
30. US Food and Drug Administration. Innovation or stagnation: Challenge and opportunity on the critical path to new medicinal products. In: FDA.gov/ScienceResearch/SpecialTopics/CriticalPath Initiative/CriticalPathOpportunitiesReports/ucm077262.htm. [Internet] [Accessed 2011 Apr 20].
31. US Food and Drug Administration. Innovation or stagnation: critical path opportunities list. In: FDA.gov/ScienceResearch/SpecialTopics/ CriticalPathInitiative/CriticalPathOpportunitiesReports/default.htm. [Internet] [Accessed 2011 Apr 20].
32. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001; 69: 89-95.
33. Lindstrom JM. Acetylcholine receptors and myasthenia. Muscle Nerve 2000; 23: 453-477.
34. Christadoss P, Poussin M, Deng C. Animal models of myasthenia gravis. Clin Immunol 2000; 94: 75-87.
35. Keymeulen B, Vandemeulebrouke C, Kaufman L, Hale G, Gorus F, Goldman M, et al. Insulin needs after CD3-antibody therapy in new-onset Type 1 diabetes. N Engl J Med 2005.
36. Traynor BJ, Bruijn L, Conwit R, Beal F, O'Neill G, Fagan SC, et al. Neuroprotective agents for clinical trials in ALS: a systematic assessment. Neurology 2006; 67: 20-27.
37. TACT: the TREAT-NMD Advisory Committee for Therapeutics. In. TREAT-NMD.eu/resources/TACT/introduction/ [Internet]. [Accessed 2011 Aug 31].
38. Rowin J. Etanercept treatment in myasthenia gravis. Ann N Y Acad Sci 2008; 1132: 300-304.
39. Janssen SPM, Phernambucq M, Martinez P, De Baets MH, Losen M. Immunosuppression of experimental autoimmune myasthenia gravis by mycophenolate mofetil. J Neuroimmunol 2008; 201: 111-120.
40. Zhou Y, Gong B, Lin F, Rother RP, Medof ME, Kaminski HJ. Anti-c5 antibody treatment ameliorates weakness in experimentally acquired myasthenia gravis. J Immunol 2007; 179: 8562-8567.
41. Hepburn NJ, Chamberlain-Banoub JL, Williams AS, Morgan BP, Harris CL. Prevention of experimental autoimmune myasthenia gravis by rat Crry-Ig: a model agent for long-term complement inhibition in vivo. Mol Immunol 2008; 45: 395-405.
42. Barker AD, Sigman CC, Kelloff GJ, Hylton NM, Berry DA, Esserman LJ. I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther 2009; 86: 97-100.
43. US Food and Drug Administration. Guidance for industry adaptive design clinical trials for drugs and biologics. In: FDA.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm. [Internet] [Accessed 2011 Apr 20].
44. Gliklich RE, Dreyer NA. Registries for evaluating patient outcomes: a user's guide. 2nd ed. AHRQ Publication No.10-EHC049. Rockville, MD: Agency for Healthcare Research and Quality. 2010.
45. Myasthenia Gravis Foundation of America. In: myasthenia.org [Internet] [Accessed 2011 Aug 31].
46. Johnston SC, Wilson CB, Halback VV, et al. Endovascular and surgical treatment of unruptured cerebral aneurysms: comparison of risks. Ann Neurol 2000; 48: 11-19.
47. D'Agostini RB. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998; 17: 2265-2281.
48. Wang L, McLeod HL, Weinshilboum RM. Genomics and drug response. N Engl J Med 2011; 364: 1144-1153.
49. Ballandina A, Sandrine L, Dartevelle P, Saoudi A, Berrih-Aknin S. Functional defect of regulatory CD4+CD25+ T cells in the thymus of patients with autoimmune myasthenia gravis. Blood 2005; 105: 735-741.
50. Strobel P, Moritz R, Leite MI, Willcox N, Chuang WY, Gold R, et al. The ageing and myasthenic thymus: a morphometric study validating a standard procedure in the histological workup of thymic specimens. J Neuroimmunol 2008; 201-202: 64-73.